Drawbacks Safety and efficacy data are unavailable for its use following >6 hours of cisplatin infusion. Less likely to reduce the ototoxicity risk when administered following longer cisplatin infusions due to the possibility of irreversible ototoxicity Lack of data on use during pregnancy and lactation Clinical trials ##Click here to read about SIOPEL 6 trial## Pediatric patients with standard risk hepatoblastoma (n=114) undergoing 6 cycles of perioperative cisplatin-based chemotherapy.
Randomization (1:1) Cisplatin alone arm: Without sodium thiosulfate Sodium thiosulfate and cisplatin arm: Cisplatin-based chemotherapy, together with sodium thiosulfate, was administered at various doses of 10 g/m 2 , 15 g/m 2 , or 20 g/m 2 based on actual body weight. Primary outcome The incidence of Brock Grade ≥1 hearing loss was lower in the sodium thiosulfate and cisplatin arm (39%) compared with…
